Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIOLET: Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2- Early Breast Cancer
NCT07428018Phase 2Not yet recruiting
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Apr 2026
- Primary completion
- Apr 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of abemaciclib in breast cancer, sponsored by Mario Negri Institute for Pharmacological Research. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
abemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07428018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07428018.